Understand the source comparison
DSIP FDA Approved Status: International Comparison
FDA (United States) Research chemical only Not approved; no IND filed No Never initiated DSIP has never entered the U.S. drug approval pathway—no safety or efficacy data exists from controlled human trials EMA (European Union) Unapproved investigational substa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- FDA (United States)
- Research chemical only
- Not approved; no IND filed
- No
- Never initiated
- DSIP has never entered the U.S. drug approval pathway—no safety or efficacy data exists from controlled human trials
- EMA (European Union)
- Unapproved investigational substance
- Not marketed; research exemption only
- Phase I/II exploratory (1980s–1990s, discontinued)
- Early-phase European trials were abandoned due to inconsistent results and lack of commercial sponsorship
- TGA (Australia)
- Schedule 4 restricted substance (investigational)
- Prohibited for human therapeutic use
- No active trials
- TGA classifies DSIP as an investigational peptide requiring import permits for research—personal use prohibited
- Health Canada
- Unapproved drug substance
- Not authorized for sale; research exemption exists
- Canadian regulations treat DSIP identically to the U.S.—research supply only, no therapeutic indication
- PMDA (Japan)
- Unapproved peptide
- Not marketed; restricted to academic research
- Historical trials only (1980s)
- Japan conducted limited DSIP research in sleep disorder contexts but never progressed to market authorization
- No major pharmaceutical regulatory authority worldwide has approved DSIP for clinical use. The European Medicines Agency (EMA) conducted Phase I and early Phase II exploratory trials in the 1980s and 1990s investigating DSIP's potential in sleep disorders and stress modulation—but these programs were discontinued without filing for market authorization. The lack of a commercial sponsor willing to fund late-phase trials is the primary barrier; DSIP cannot be patented as a novel molecule because it was discovered in 1977, eliminating the financial incentive for pharmaceutical companies to invest in its development.